Fri, May 30, 2025
Volume 16, Issue 1 (Jan-Feb 2022)
mljgoums 2022, 16(1): 13-19 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mulani J, Murhar B, Jambhulkar R, Mishra G. Serum Prolactin: A Clue to Breast Malignancy. mljgoums 2022; 16 (1) :13-19
URL: http://mlj.goums.ac.ir/article-1-1450-en.html
URL: http://mlj.goums.ac.ir/article-1-1450-en.html
1- Department of Vector Borne Diseases, Nagpur Municipal Corporation, Nagpur, Maharashtra, India - In Charge Medical Officer, Vector Borne Diseases, Nagpur Municipal Corporation, Nagpur, India
2- Professor and Head, Biochemistry, Government Medical College and Hospital, Nagpur, India
3- Assistant Professor, Biochemistry, Government Medical College and Hospital, Nagpur, India
4- Associate Professor, Respiratory Medicine, Indira Gandhi Government Medical College and Hospital, Nagpur, India ,gpmishra81@gmail.com
2- Professor and Head, Biochemistry, Government Medical College and Hospital, Nagpur, India
3- Assistant Professor, Biochemistry, Government Medical College and Hospital, Nagpur, India
4- Associate Professor, Respiratory Medicine, Indira Gandhi Government Medical College and Hospital, Nagpur, India ,
Abstract: (5087 Views)
Background and objectives: Prolactin is a lactogenic protein hormone secreted by the anterior pituitary that initiates and maintains lactation in mammals. Previous research has linked increased serum prolactin levels to breast cancer. However, there is a paucity of studies in the Indian population on the subject. The present study evaluated and compared serum prolactin levels in patients with breast cancer and patients with benign breast diseases.
Methods: This cross-sectional, comparative study was carried out at the Government Medical College, Nagpur (India) on patients with breast diseases in the out-patient department/in-patient department from June 2018 to November 2020. Breast cancer patients were considered cases, and those with benign breast diseases were considered controls. Breast carcinoma diagnosis was based on clinical features, fine needle aspiration cytology, and tissue histopathology in operated specimens for each patient. Fasting serum prolactin levels were measured by the chemiluminescence immunoassay method using the Advia Centaur immunoassay system.
Results: There were 120 female patients with breast diseases, of whom 60 had breast malignancy, and 60 had benign breast diseases. The mean age of patients with benign breast disease and breast cancer was 33.17 (1.75) and 49.77 (1.16) years, respectively (P<0.0005). Increased serum prolactin levels were observed in 93.3% of patients with breast cancer and 13.3% of patients with benign breast diseases. The mean serum prolactin level was significantly higher among breast cancer patients (102.68±7.03) ng/ml compared with patients with benign breast disease (16.31±1.72 ng/ml). We successfully determined a new cut-off value of serum prolactin level (>40.2 ng/ml) to differentiate breast cancer from benign breast diseases using the receiver operating characteristic curve analysis.
Conclusion: Patients with breast cancer have increased serum prolactin levels compared to patients with benign breast diseases. Thus, serum prolactin level can be used as a diagnostic marker for breast cancer. This is particularly beneficial to clinicians for differentiating breast cancer from benign breast diseases.
Methods: This cross-sectional, comparative study was carried out at the Government Medical College, Nagpur (India) on patients with breast diseases in the out-patient department/in-patient department from June 2018 to November 2020. Breast cancer patients were considered cases, and those with benign breast diseases were considered controls. Breast carcinoma diagnosis was based on clinical features, fine needle aspiration cytology, and tissue histopathology in operated specimens for each patient. Fasting serum prolactin levels were measured by the chemiluminescence immunoassay method using the Advia Centaur immunoassay system.
Results: There were 120 female patients with breast diseases, of whom 60 had breast malignancy, and 60 had benign breast diseases. The mean age of patients with benign breast disease and breast cancer was 33.17 (1.75) and 49.77 (1.16) years, respectively (P<0.0005). Increased serum prolactin levels were observed in 93.3% of patients with breast cancer and 13.3% of patients with benign breast diseases. The mean serum prolactin level was significantly higher among breast cancer patients (102.68±7.03) ng/ml compared with patients with benign breast disease (16.31±1.72 ng/ml). We successfully determined a new cut-off value of serum prolactin level (>40.2 ng/ml) to differentiate breast cancer from benign breast diseases using the receiver operating characteristic curve analysis.
Conclusion: Patients with breast cancer have increased serum prolactin levels compared to patients with benign breast diseases. Thus, serum prolactin level can be used as a diagnostic marker for breast cancer. This is particularly beneficial to clinicians for differentiating breast cancer from benign breast diseases.
Research Article: Original Paper |
Subject:
Biochemistry
Received: 2021/10/19 | Accepted: 2021/12/11 | Published: 2021/12/29 | ePublished: 2021/12/29
Received: 2021/10/19 | Accepted: 2021/12/11 | Published: 2021/12/29 | ePublished: 2021/12/29
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-49. [View at Publisher] [DOI:10.3322/caac.21660] [PubMed] [Google Scholar]
2. Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017;13(4):289-95. [View at Publisher] [DOI:10.1111/ajco.12661] [PubMed] [Google Scholar]
3. WHO. Breast cancer (Internet). (cited 2020 May 27). Available from: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/ [View at Publisher]
4. Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nature Reviews Endocrinology. 2019;15(6): 356-65. [View at Publisher] [DOI:10.1038/s41574-019-0194-6] [PubMed] [Google Scholar]
5. Wang M, Wu X, Chai F, Zhang Y, Jiang J. Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep. 2016;6(1):25998. [DOI:10.1038/srep25998] [Google Scholar]
6. Ali JK, Hassan SH, Merzah MA, Ali, Hassan SH, Merzah MA. Prolactin serum levels and breast cancer: Relationships with hematological factors among cases in Karbala Province, Iraq. Med J Babylon. 2018; 15(2): 178. [View at Publisher] [Google Scholar]
7. Alhaj A. Serum Prolactin Level in Yemeni Females with Breast Cancer. YEMENI J Med Sci. 2012; 6: 1-6. [View at Publisher]
8. Walia BS, Kapur V, Nyitan T, Kiranjot, Singh R, Neki NS. A Comparative Evaluation of serum Prolactin levels in pre-operative and post operative carcinoma breast patients. Int J Curr Res Med Sci. 2017; 3(4): 113-9. [View at Publisher] [DOI:10.22192/ijcrms.2017.03.04.016]
9. Saravanan P, ANu S. Estimation of Prolactin Level in Women with Carcinoma Breast. Indian J Clin Anat Physiol. 2017; 4(3):381-5. [View at Publisher] [Google Scholar]
10. Tworoger SS, Eliassen a H, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007; 25(12):1482-8. [View at Publisher] [DOI:10.1200/JCO.2006.07.6356] [Google Scholar]
11. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger C V. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology. 1997; 138(12): 5555-60. [DOI:10.1210/endo.138.12.5605] [PubMed] [Google Scholar]
12. Tikk K, Sookthai D, Fortner RT, Johnson T, Rinaldi S, Romieu I, et al. Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: A case-control study. Breast Cancer Res. 2015;17(1):49. [View at Publisher] [DOI:10.1186/s13058-015-0563-6] [PubMed] [Google Scholar]
13. Dekkers OM, Ehrenstein V, Bengtsen M, Farkas DK, Pereira AM, Sørensen HT, et al. Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. Eur J Endocrinol. 2015;173(2):269-73. [DOI:10.1530/EJE-15-0282] [PubMed] [Google Scholar]
14. Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Res. 2009;69(7):3165-72. [DOI:10.1158/0008-5472.CAN-08-4033] [PubMed] [Google Scholar]
15. Clevenger C V., Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocrine Reviews. 2003;24(1):1-27. [View at Publisher] [DOI:10.1210/er.2001-0036] [PubMed] [Google Scholar]
16. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JMP. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer. 2004; 91(2): 305-311. [View at Publisher] [DOI:10.1038/sj.bjc.6601947] [PubMed] [Google Scholar]
17. Mujagic Z, Srabovic N, Mujagic H. The role of prolactin in human breast cancer. Biochem Medica. 2009; 19(3): 236-49. [View at Publisher] [DOI:10.11613/BM.2009.022] [Google Scholar]
18. Sethi, Chanukya G, Nagesh VS. Prolactin and cancer: Has the orphan finally found a home? Indian J Endocrinol Metab. 2012;16(8):195. [View at Publisher] [PubMed] [Google Scholar]
19. Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: New therapeutic implications. Mol Cell Endocrinol. 2009;307(1-2):1-7. [View at Publisher] [DOI:10.1016/j.mce.2009.03.014] [PubMed] [Google Scholar]
20. Reuwer AQ, Nowak-Sliwinska P, Mans LA, van der Loos CM, von der Thüsen JH, Twickler MTB, et al. Functional consequences of prolactin signalling in endothelial cells: A potential link with angiogenesis in pathophysiology? J Cell Mol Med. 2012;16(9):2035-48. [View at Publisher] [DOI:10.1111/j.1582-4934.2011.01499.x] [PubMed] [Google Scholar]
21. Sa-Nguanraksa D, Thasripoo C, Samarnthai N, Kummalue T, Thumrongtaradol T, O-Charoenrat P. The role of prolactin/prolactin receptor polymorphisms and expression in breast cancer susceptibility and outcome. Transl Cancer Res. 2020;9(10):6344-53. [View at Publisher] [DOI:10.21037/tcr-20-1120] [Google Scholar]
22. Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: An update on physiology and current analytical issues. Clinical Biochemist Reviews. 2018; 39(1): 3-16. [PubMed] [Google Scholar]
23. Damiano JS, Wasserman E. Molecular pathways: Blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res. 2013;19(7):1644-50. [View at Publisher] [DOI:10.1158/1078-0432.CCR-12-0138] [PubMed] [Google Scholar]
24. Farzami MR, Aliasgharpour M. Chemiluminescence systems; do all lead to same results in prolactin analysis? J Diabetes Metab Disord. 2017;16(24):1-4. [View at Publisher] [DOI:10.1186/s40200-017-0305-7] [PubMed] [Google Scholar]
25. Kavanagh L, McKenna TJ, Fahie-Wilson MN, Gibney J, Smith TP. Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem. 2006; 52(7): 1366-72. [View at Publisher] [DOI:10.1373/clinchem.2005.065854] [PubMed] [Google Scholar]
26. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. [View at Publisher] [DOI:10.3322/caac.21654] [PubMed] [Google Scholar]
27. Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, et al. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Netw Open. 2021;4(6):e2114716. [View at Publisher] [DOI:10.1001/jamanetworkopen.2021.14716] [PubMed] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.